Market Research Logo

Vectura Group Plc - Product Pipeline Review - 2015

Vectura Group Plc - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Vectura Group plc - Product Pipeline Review - 2015’, provides an overview of the Vectura Group plc’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vectura Group plc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Vectura Group plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vectura Group plc’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vectura Group plc’s pipeline products
Reasons to buy
  • Evaluate Vectura Group plc’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vectura Group plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vectura Group plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vectura Group plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vectura Group plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vectura Group plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


Vectura Group Plc Snapshot
Vectura Group Plc Overview
Key Information
Key Facts
Vectura Group Plc - Research and Development Overview
Key Therapeutic Areas
Vectura Group Plc - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Vectura Group Plc - Pipeline Products Glance
Vectura Group Plc - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Vectura Group Plc - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Vectura Group Plc - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Vectura Group Plc - Drug Profiles
VR-475
Product Description
Mechanism of Action
R&D Progress
VR-876
Product Description
Mechanism of Action
R&D Progress
VR-096
Product Description
Mechanism of Action
R&D Progress
VR-647
Product Description
Mechanism of Action
R&D Progress
VR-736
Product Description
Mechanism of Action
R&D Progress
Drug for Pulmonary Hypertension
Product Description
Mechanism of Action
R&D Progress
VR-588
Product Description
Mechanism of Action
R&D Progress
Vectura Group Plc - Pipeline Analysis
Vectura Group Plc - Pipeline Products by Target
Vectura Group Plc - Pipeline Products by Route of Administration
Vectura Group Plc - Pipeline Products by Molecule Type
Vectura Group Plc - Pipeline Products by Mechanism of Action
Vectura Group Plc - Recent Pipeline Updates
Vectura Group Plc - Dormant Projects
Vectura Group Plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
VR-611
Vectura Group Plc - Company Statement
Vectura Group Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Vectura Group Plc, Key Information
Vectura Group Plc, Key Facts
Vectura Group Plc - Pipeline by Indication, 2015
Vectura Group Plc - Pipeline by Stage of Development, 2015
Vectura Group Plc - Monotherapy Products in Pipeline, 2015
Vectura Group Plc - Partnered Products in Pipeline, 2015
Vectura Group Plc - Partnered Products/ Combination Treatment Modalities, 2015
Vectura Group Plc - Out-Licensed Products in Pipeline, 2015
Vectura Group Plc - Out-Licensed Products/ Combination Treatment Modalities, 2015
Vectura Group Plc - Phase III, 2015
Vectura Group Plc - Phase II, 2015
Vectura Group Plc - Phase I, 2015
Vectura Group Plc - Preclinical, 2015
Vectura Group Plc - Pipeline by Target, 2015
Vectura Group Plc - Pipeline by Route of Administration, 2015
Vectura Group Plc - Pipeline by Molecule Type, 2015
Vectura Group Plc - Pipeline Products by Mechanism of Action, 2015
Vectura Group Plc - Recent Pipeline Updates, 2015
Vectura Group Plc - Dormant Developmental Projects,2015
Vectura Group Plc - Discontinued Pipeline Products, 2015
Vectura Group Plc, Subsidiaries
List of Figures
Vectura Group Plc - Pipeline by Top 10 Indication, 2015
Vectura Group Plc - Pipeline by Stage of Development, 2015
Vectura Group Plc - Monotherapy Products in Pipeline, 2015
Vectura Group Plc - Partnered Products in Pipeline, 2015
Vectura Group Plc - Out-Licensed Products in Pipeline, 2015
Vectura Group Plc - Pipeline by Top 10 Target, 2015
Vectura Group Plc - Pipeline by Top 10 Route of Administration, 2015
Vectura Group Plc - Pipeline by Top 10 Molecule Type, 2015
Vectura Group Plc - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report